GLP-1 RAs in Chronic Migraine - Takeaways - MDSpire

GLP-1 RAs in Chronic Migraine

Investigators evaluate health care utilization and treatment patterns vs topiramate in an active-comparator study.

  • By

  • Kathryn Wighton

  • March 3, 2026

  • 3 min

Share

  • 1

    GLP-1 receptor agonists were associated with lower emergency department visits and hospitalizations compared to topiramate in chronic migraine patients.

  • 2

    The study included 10,997 patients in each cohort, with a mean age of 48 years and 88% being female.

  • 3

    Patients initiating GLP-1 RAs had a lower risk of nerve block procedures and triptan prescriptions compared to those on topiramate.

  • 4

    GLP-1 RA users were less likely to start additional preventive medications, including valproate and CGRP monoclonal antibodies.

  • 5

    The study highlights the need for randomized controlled trials to assess the preventive efficacy of GLP-1 RAs in migraine.

Original Source(s)

GLP-1 RAs in Chronic Migraine

  • by Kathryn Wighton

  • March 3, 2026

Related Content

Integrating multi-omics and machine learning to explore the role of amino acid metabolism in intervertebral disk degeneration

Astigmatism Up After COVID Restrictions

Researchers identified delayed corneal changes in schoolchildren that emerged after myopia rates had already increased during the pandemic.

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.